Abstract:Objective: This paper is a proposal for an update of the iron hypothesis of Alzheimer's disease (AD), based on large-scale emerging evidence. Background: Iron featured historically early in AD research efforts for its involvement in the amyloid and tau proteinopathies, APP processing, genetics, and one clinical trial, yet iron neurochemistry remains peripheral in mainstream AD research. Much of the effort investigating iron in AD has focused on the potential for iron to provoke the onset of disease, by promoting proteinopathy though increased protein expression, phosphorylation, and aggregation. New/updated hypothesis: We provide new evidence from a large post mortem cohort that brain iron levels within the normal range were associated with accelerated ante mortem disease progression in cases with underlying proteinopathic neuropathology. These results corroborate recent findings that argue for an additional downstream role for iron as an effector of neurodegeneration, acting independently of tau or amyloid pathologies. We hypothesize that the level of tissue iron is a trait that dictates the probability of neurodegeneration in AD by ferroptosis, a regulated cell death pathway that is initiated by signals such as glutathione depletion and lipid peroxidation. Major challenges for the hypothesis: While clinical biomarkers of ferroptosis are still in discovery, the demonstration of additional ferroptotic correlates (genetic or biomarker derived) of disease progression is required to test this hypothesis. The genes implicated in familial AD are not known to influence ferroptosis, although recent reports on APP mutations and apolipoprotein E allele (APOE) have shown impact on cellular iron retention. Familial AD mutations will need to be tested for their impact on ferroptotic vulnerability. Ultimately, this hypothesis will be substantiated, or otherwise, by a clinical trial of an anti-ferroptotic/iron compound in AD patients. Linkage to other major theories: Iron has historically been linked to the amyloid and tau proteinopathies of AD. Tau, APP, and apoE have been implicated in physiological iron homeostasis in the brain. Iron is biochemically the origin of most chemical radicals generated in biochemistry and thus closely associated with the oxidative stress theory of AD. Iron accumulation is also a well-established consequence of aging and inflammation, which are major theories of disease pathogenesis.

Iron associated lipid peroxidation in Alzheimers disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice

Iron Enhances The Neurotoxicity Of Amyloid Beta

Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications

Iron Dyshomeostasis and Ferroptosis: A New Alzheimer’s Disease Hypothesis?

Iron Enhances the Neurotoxicity of Amyloid β

Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease

Iron Pathophysiology in Alzheimer's Diseases.

Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy

Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer’s Disease

Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins

Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance

Iron Metabolism, Ferroptosis, and the Links With Alzheimer's Disease

Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease

Brain Iron Dyshomeostasis and Ferroptosis in Alzheimer's Disease Pathophysiology: Two Faces of the Same Coin

Ferroptosis Signaling Pathways: Alzheimer's Disease

Iron Exposure and the Cellular Mechanisms Linked to Neuron Degeneration in Adult Mice

Iron Chelation Remits Memory Deficits Caused by the High-Fat Diet in a Mouse Model of Alzheimer's Disease

Ferroptosis, a Potential Therapeutic Target in Alzheimer’s Disease

Redox-active metals, oxidative stress, and Alzheimer's disease pathology.

Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation As Potential Alzheimers Therapies

Apolipoprotein E is required for brain iron homeostasis in mice